CSIMarket
 
Neuropace Inc   (NPCE)
Other Ticker:  
 
 
Price: $13.1800 $-0.45 -3.302%
Day's High: $13.88 Week Perf: -3.09 %
Day's Low: $ 13.07 30 Day Perf: -14.75 %
Volume (M): 117 52 Wk High: $ 18.15
Volume (M$): $ 1,546 52 Wk Avg: $7.77
Open: $13.66 52 Wk Low: $3.42



 Market Capitalization (Millions $) 343
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) 59
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Neuropace Inc
Neuropace Inc is a medical device company that specializes in developing and manufacturing neurostimulation systems for the treatment of neurological disorders. The company is known for its innovative RNS System, which stands for Responsive Neurostimulation System. This system is designed to detect and respond to abnormal electrical activity in the brain, providing therapy to patients suffering from epilepsy.

The RNS System consists of a small implantable device that is placed in the skull and connected to electrodes placed on or in the brain. It continuously monitors brain activity and delivers electrical pulses in response to abnormal patterns, helping to prevent seizures.

Neuropace Inc's RNS System is the first and only FDA-approved brain-responsive neurostimulation system for the treatment of refractory epilepsy. It offers a personalized and adaptive approach to managing seizures, with the potential to improve the quality of life for patients who are not adequately controlled by medication alone.

The company is headquartered in Mountain View, California, and operates globally, offering its neurostimulation technology to patients and healthcare professionals worldwide. Neuropace Inc is committed to further advancing the field of neuromodulation and exploring the potential of neurostimulation for the treatment of various neurological disorders.


   Company Address: 455 N. Bernardo Avenue Mountain View 94043 CA
   Company Phone Number: 237-2700   Stock Exchange / Ticker: NASDAQ NPCE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

NeuroPace Reports Promising Revenue Growth for Q4 2023 and Full Year 2023, Despite Recent Financial Setbacks

Published Mon, Jan 8 2024 12:03 PM UTC


NeuroPace, a leading medical technology company specializing in neuromodulation therapies, announced its preliminary unaudited revenue for the fourth quarter and full year 2023, along with some important business updates. The company expects its revenue for Q4 2023 to fall between $17.5 million and $18.0 million, while the full-year revenue is projected to be in the ran...

Clinical Study

NeuroPace's Landmark Study Brings New Hope for Drug Refractory Epilepsy Patients, Fuels Impressive Revenue Growth

Published Thu, Dec 21 2023 12:07 PM UTC

NeuroPace Inc., a leading pioneer in neurostimulation technology, has recently announced the successful completion of patient enrollment in its groundbreaking NAUTILUS Pivotal Study. NAUTILUS is the first-ever pivotal clinical trial aimed at evaluating the effectiveness of neuromodulation therapy in treating drug refractory idiopathic generalized epilepsy. This significant m...

Neuropace Inc

NPCE's Remarkable Performance Steals the Show in Latest Fiscal Period!

NeuroPace Inc, a medical device company focused on epilepsy treatment, has reported its financial results for the third quarter of 2023. Despite the ongoing challenges posed by the pandemic, the company has showcased a strong performance during this period.
During the financial third quarter of 2023, NeuroPace Inc posted a decrease in loss per share to $-0.28 per share, compared to $-0.48 per share in the same quarter a year ago. This is a positive indication of the company's improving financial health. Additionally, the earnings per share (EPS) improved from $-0.36 per share in the previous reporting season.

Neuropace Inc

Neuropace Inc Achieves Impressive Revenue Growth and Drastically Reduces Losses in Q2 2023



Neuropace Inc, a leading player in the industry, has recently released its financial results for the second quarter of 2023. The impressive revenue growth and improved earnings per share (EPS) in this quarter signify positive developments for the company. Additionally, the reduction of losses compared to the previous year showcases Neuropace Inc's commitment to improving its financial performance. Examining the implications of these results could shed light on the company's future prospects and potential challenges.
1. Revenue Growth and EPS Improvement:
Neuropace Inc experienced a remarkable 56.588% increase in revenue, reaching $15.97 million in the second quarter of the 2023 earnings season. This growth is a significant improvement compared to the same period last year and signifies the company's ability to attract more clients or increase sales to existing customers. Moreover, the decrease in losses per share from $-0.52 to $-0.36 is a positive indication of Neuropace Inc's efforts to mitigate financial challenges and move closer to profitability.

Neuropace Inc

NPCE Reduces Losses in Q1 2023, Boosts Revenue by 27%2. Neuropace Inc Surpasses Expectations in Q1 2023 with Lower Losses and Increased Revenue3. Strong Performance in Q1 2023: Neuropace Inc Bounces Back with Improved Financials4. Neuropace Inc Shows Promising Results in Q1 2023, Decreases Losses and Boosts Revenue5. Q1 2023 Earnings Report: Neuropace Inc Achieves Significant Growth, Narrows Losses

Investors of Neuropace Inc can breathe a sigh of relief as the company has performed reasonably well in the first quarter of 2023 earnings season. According to the financial report for the quarter ending March 31, 2023, the company recorded a decrease in its loss per share from $-0.47 a year ago to $-0.41 per share. Further, the EPS of the company improved from $-0.44 per share in the preceding financial reporting period.
More interestingly, the revenue of Neuropace Inc increased substantially by 27.238 % to $14.47 million from $11.37 million in the comparable financial reporting period a year ago. Further, the revenue sequentially advanced by 13.16 % from $12.79 million. This massive improvement in the company's revenue is a testament to the management's diligent efforts to turn things around.






 

Neuropace Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com